[Multiple sclerosis: can therapy delay ongoing disability?]

MMW Fortschr Med. 2011 Apr 7;153(14):63-6.
[Article in German]
No abstract available

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Brain / drug effects
  • Brain / pathology
  • Disability Evaluation*
  • Disease Progression
  • Glatiramer Acetate
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Interferons / therapeutic use
  • Magnetic Resonance Imaging
  • Multiple Sclerosis / classification
  • Multiple Sclerosis / diagnosis
  • Multiple Sclerosis / psychology
  • Multiple Sclerosis / rehabilitation*
  • Natalizumab
  • Neurologic Examination / drug effects
  • Neuroprotective Agents / therapeutic use
  • Peptides / therapeutic use
  • Quality of Life / psychology
  • Wheelchairs

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Immunosuppressive Agents
  • Natalizumab
  • Neuroprotective Agents
  • Peptides
  • Glatiramer Acetate
  • Interferons